Sugi Predict

Sugi Predict / Compounds / SCHEMBL3499337

SCHEMBL3499337

SCHEMBL3499337

CC(C)Oc1cccc(OC(C)C)c1-c1ccc(C2CCCCC2)c(C2CCCCC2)c1P

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALOX5AP P20292 1/20 0.37
▸ FEN1 P39748 1/20 0.37
▸ ADRA2A P08913 2/20 0.36
▸ ADRA2B P18089 2/20 0.36
▸ ADRA2C P18825 2/20 0.36
▸ ABCB1 P08183 2/20 0.36
▸ HTR1A P08908 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ HTR2A P28223 1/20 0.33
▸ HTR2C P28335 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ IKBKB O14920 1/20 0.33
▸ PTGDR2 Q9Y5Y4 3/20 0.33
▸ PTGDR Q13258 1/20 0.33
▸ CAMKK2 Q96RR4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28278174 0.86 ADRA2A (0.35) ALOX5APFEN1ADRA2AADRA2BADRA2C
SCHEMBL22275 0.85 ABCB1 (0.47) ALOX5APFEN1ABCB1HTR1AHTR2C
SCHEMBL29392064 0.85 ADRA2A (0.41) ALOX5APFEN1ADRA2AADRA2BADRA2C
SCHEMBL19809959 0.81 ALOX5AP (0.35) ALOX5APFEN1ADRA2AADRA2BADRA2C
SCHEMBL28483732 0.81 CAMKK2 (0.41) ALOX5APFEN1ADRA2AADRA2BADRA2C
SCHEMBL19643363 0.80 CA1 (0.36) ALOX5APFEN1ADRA2AADRA2BADRA2C
SCHEMBL851115 0.78 HTR2C (0.34) FEN1ABCB1HTR1AHTR2C
SCHEMBL28999533 0.77 ALOX5AP (0.42) ALOX5APFEN1ADRA2AADRA2BADRA2C
SCHEMBL28000628 0.75 ABCB1 (0.47) ALOX5APFEN1ABCB1HTR1A
SCHEMBL19182356 0.75 HTR1A (0.35) ABCB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109661399-A Cross-coupling methods 芝诺罗耶尔蒂里程碑有限责任公司 2019-04-19 — — CN claimed
WO-2023247416-A1 TETRAARYLBENZIDINE TYPE COMPOUNDS AND THEIR USE IN ORGANIC ELECTRONICS DOTTIKON ES HOLDING AG (CH) 2023-12-28 — — WO disclosed
WO-2023178130-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-09-21 — — WO disclosed
WO-2023107603-A1 PYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023107552-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 — — WO disclosed
WO-2023078824-A1 SPIRO-(INDANE-FLUORENE) TYPE COMPOUNDS AND THEIR USE IN ORGANIC ELECTRONICS DOTTIKON ES HOLDING AG (CH) 2023-05-11 — — WO disclosed
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-02-16 — — US disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 — — EP disclosed
US-20230002371-A1 RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2023-01-05 — — US disclosed
US-20220006020-A1 DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS DOTTIKON ES HOLDING AG (CH) 2022-01-06 — — US disclosed
WO-2015044073-A1 PROCESS AND INTERMEDIATES FOR PREPARING INDANYLOXYDIHYDROBENZOFURANYL ACETIC ACID DERIVATIVES AS GPR40 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-04-02 — — WO disclosed
CN-103917522-A Process for producing N- (hetero) arylazoles TAKASAGO PERFUMERY CO LTD 2014-07-09 — — CN disclosed
WO-2014031468-A1 NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 — — WO disclosed
WO-2014031441-A1 NOVEL BENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 — — WO disclosed
WO-2014031517-A1 NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 — — WO disclosed
WO-2014031465-A1 NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 — — WO disclosed
WO-2014031515-A1 NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 — — WO disclosed
WO-2014031445-A1 NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-02-27 — — WO disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 — — US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 ALOX5AP 2433/4885FEN1 4836/4885ADRA2A 313/4885
US-20220006020-A1 DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS NR0B2, KCNJ2, TRRAP ALOX5AP 4199/4885FEN1 4359/4885ADRA2A 302/4885
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES BRCA1, MYC, PCNA ALOX5AP 2312/4885FEN1 321/4885ADRA2A 4141/4885
US-20230002371-A1 RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS KRAS, RSU1, RAB1A ALOX5AP 3976/4885FEN1 3200/4885ADRA2A 3430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.